The Novartis dug company is in advanced talks to buy up Israeli-based stem cell treatments developer Gamida-Cell for $600 million, sources told the Globes business newspaper.
Slightly more than half of Gamida-Cell is owned by Clal Biotechnology and Elbit Medical Technologies, a subsidiary of Elbit Imaging.
Gamida-Cell has been considering offering an IPO on Wall Street, but the reported purchasing price offered by Novartis is far more than the revenues it would raise on its own.
Gamida Cell has proprietary technology for growing the number and density of stem cells within a specific blood sample and seeks to enhance umbilical cord blood donations for implants to cure blood cancer in adults.
Currently, umbilical cord blood can only be used for implant in people weighing less than 90 pounds, according to Globes.
About the Author: JewishPress.com brings you the latest in Jewish news from around the world. Stay up to date by following up on Facebook and Twitter. Do you have something noteworthy to report? Submit your news story to us here.
If you don't see your comment after publishing it, refresh the page.
Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.
If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.